Literature DB >> 6384722

Carbohydrate dynamics in the hypermetabolic septic rat.

C H Lang, G J Bagby, J J Spitzer.   

Abstract

Glucose turnover is increased during shock and in acute sepsis, but relatively little information is available concerning the regulation of carbohydrate metabolism during the hypermetabolic phase of sepsis. In these studies peritoneal sepsis was induced in rats, following chronic vascular catheterization, by intraperitoneal administration of a pooled fecal inoculum. The resultant peritonitis has been shown to produce a sustained hypermetabolic state during the first three days of infection. Glucose and lactate kinetics were studied using a constant infusion of radiolabeled tracers during the peak of the hypermetabolic phase (day 2). The septic animals exhibited a 42% increase in glucose turnover and a 63% increase in the metabolic clearance rate of glucose, as compared to time-matched control rats. Hepatic glycogenolysis could only contribute 1% to 2% to the increased rate of glucose appearance. A major portion of the elevated glucose turnover was accounted for by a 93% increase in glucose recycling, indicating an enhancement of gluconeogenesis from glucose-derived gluconeogenic precursors. The increased importance of lactate as a precursor for gluconeogenesis in sepsis was indicated by the elevated lactate turnover (34%) and the increased percentage of 14C-glucose derived from 14C-lactate. The insulin to glucagon ratio was decreased in the septic animals as a result of a reduction in the plasma insulin concentration (56%) and an increased glucagon concentration (67%). We conclude that during the hypermetabolic phase of sepsis, the increased peripheral glucose uptake generated more gluconeogenic precursors but did not appear to have a major direct contribution to the increased aerobic metabolism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6384722     DOI: 10.1016/0026-0495(84)90251-8

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Modulation of endogenous hormone action by recombinant human tumor necrosis factor.

Authors:  R S Warren; D B Donner; H F Starnes; M F Brennan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

Review 2.  Hyperglycemia in critical illness: a review.

Authors:  David Brealey; Mervyn Singer
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

3.  NF-κB-dependent airway inflammation triggers systemic insulin resistance.

Authors:  Travis J Cyphert; Robert T Morris; Lawrence M House; Tammy M Barnes; Yolanda F Otero; Whitney J Barham; Raphael P Hunt; Rinat Zaynagetdinov; Fiona E Yull; Timothy S Blackwell; Owen P McGuinness
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-09-16       Impact factor: 3.619

4.  G1 cell cycle arrest signaling in hepatic injury after intraperitoneal sepsis in rats.

Authors:  Quan-hui Yang; Da-wei Liu; Xiao-ting Wang; Rong-li Yang; Yan Shi; Yun Long; Hong-zhong Liu; Huai-wu He; Xiang Zhou; Bo Tang
Journal:  Inflamm Res       Date:  2011-04-27       Impact factor: 4.575

5.  Kinetics of diacylglycerol accumulation in response to vasopressin stimulation in hepatocytes of continuously endotoxaemic rats.

Authors:  E B Rodriguez de Turco; J A Spitzer
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

6.  Insulin regulates IL-1alpha, Ifn-y and IL-4 release from murine splenocytes stimulated with staphylococcal protein A, toxic shock syndrome toxin-1 and streptococcal lysin S.

Authors:  L Sommese; P Scarfogliero; M Vitiello; F Gorga; M Galdiero
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

7.  The association of early combined lactate and glucose levels with subsequent renal and liver dysfunction and hospital mortality in critically ill patients.

Authors:  Pedro Freire Jorge; Nienke Wieringa; Eva de Felice; Iwan C C van der Horst; Annemieke Oude Lansink; Maarten W Nijsten
Journal:  Crit Care       Date:  2017-08-21       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.